{"schema":"https://ver.cy/schemas/card/1.0.0","id":"vr.tr.levodropropizine","code":"thing-q408131","url":"https://ver.cy/models/thing/q408131/","name":"levodropropizine","alternateNames":[],"kind":"thing","status":"published","version":"0.1.0-research.1","language":"en","classifiers":{"family":"Thing Registry","category":"Physical world and living systems","entryKind":"thing","plane":"PHY","domain":["PHY.MAT"],"industry":[],"navPath":"","tags":[],"facets":{}},"whatItIs":"Levodropropizine is the (S)-enantiomer of dropropizine, a small-molecule pharmaceutical substance used as a predominantly peripherally acting antitussive for symptomatic relief of nonproductive cough.","purpose":"Enable an agent to recognise levodropropizine, assess the identity and quality of a material sample, and determine which handling or use decisions require further evidence.","scope":{"in":["Molecular identity and distinction from racemic dropropizine","Chemical assay, enantiomeric composition, impurities, and material grade","Physical form, measured properties, stability, and storage condition","Substance-level pharmacological role and limits of supporting evidence","Chemical safety and jurisdiction-specific identity and use restrictions"],"out":["Finished syrups, tablets, brands, excipients, and packaging specifications","Patient diagnosis, prescribing, dose selection, and treatment monitoring","Manufacturing plants and detailed synthesis process execution","Racemic dropropizine or the opposite enantiomer as independently modelled substances","Clinical trial operations and commercial marketing authorisations as standalone entities"],"boundaries":[]},"distinguishingFeatures":["Require the S configuration of the stereocentre: levodropropizine is the S-enantiomer of dropropizine, whereas dropropizine is racemic. [Comparative study](https://pubmed.ncbi.nlm.nih.gov/1295724/)","Match the structure of (2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol; molecular formula alone cannot distinguish its enantiomer. [PubChem identity](https://pubchem.ncbi.nlm.nih.gov/compound/Levodropropizine)","Cross-check CAS 99291-25-5 and PubChem CID 65859 against the structure rather than accepting a trade name as substance identification. [PubChem identifiers](https://pubchem.ncbi.nlm.nih.gov/compound/Levodropropizine)","Distinguish the active substance from a medicinal preparation containing it: a syrup concentration identifies a formulation property, not the purity of bulk levodropropizine. [Registered product information](https://verification.fda.gov.ph/files/DRP-11632-01_PI_01.pdf)"],"structure":{"bundles":[{"id":"substance-and-stereochemistry","name":"Substance and stereochemistry","description":"Establish exactly which molecular entity the levodropropizine entry represents.","layers":[{"id":"molecular-identity","name":"Molecular identity","description":"Resolve identifiers against a stereochemically explicit structure.","findings":[{"id":"identity-agreement","name":"Identity agreement","description":"Record whether the name, identifier, and supplied structure consistently identify levodropropizine.","questions":[{"text":"Does the supplied structure specify the S configuration of (2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol?","id":"identity-agreement-q01","kind":"definition"},{"text":"Which authoritative record supports the identifier-to-structure mapping, and when was it checked?","id":"identity-agreement-q02","kind":"provenance"}]}]},{"id":"racemate-and-product-boundaries","name":"Racemate and product boundaries","description":"Separate the registered substance from stereochemical mixtures and preparations.","findings":[{"id":"represented-entity","name":"Represented entity","description":"Determine whether a record describes levodropropizine itself, racemic material, a chemically modified form, or a formulated product.","questions":[{"text":"Does the record describe the S-enantiomer, racemic dropropizine, or material whose stereochemistry remains unspecified?","id":"represented-entity-q01","kind":"boundary"},{"text":"Is a claimed concentration or identifier attached to the active substance, a salt, or a finished medicine?","id":"represented-entity-q02","kind":"boundary"}]}]}]},{"id":"assay-and-chiral-quality","name":"Assay and chiral quality","description":"Assess bulk material using separate chemical and stereochemical evidence.","layers":[{"id":"chemical-content","name":"Chemical content","description":"Establish assay and impurity results on a stated analytical basis.","findings":[{"id":"batch-assay-and-residues","name":"Batch assay and residues","description":"Keep levodropropizine content, related substances, and residual solvents distinguishable.","questions":[{"text":"What levodropropizine assay was measured, by which method, and on what moisture or drying basis?","id":"batch-assay-and-residues-q01","kind":"measurement"},{"text":"Which impurity and residual-solvent limits apply to this grade, and which results remain unreported?","id":"batch-assay-and-residues-q02","kind":"provenance"}]}]},{"id":"enantiomeric-control","name":"Enantiomeric control","description":"Evaluate evidence that distinguishes S and R material.","findings":[{"id":"chiral-acceptance","name":"Chiral acceptance","description":"Treat stereochemical acceptance as an explicit decision supported by a suitable method.","questions":[{"text":"What S:R ratio or enantiomeric excess was measured, and can the method resolve and quantify the opposite enantiomer?","id":"chiral-acceptance-q01","kind":"measurement"},{"text":"Which specification defines the permissible opposite-enantiomer content and the disposition of a failing batch?","id":"chiral-acceptance-q02","kind":"action"}]}]}]},{"id":"physical-condition-and-stability","name":"Physical condition and stability","description":"Describe the actual material and the conditions under which its properties remain applicable.","layers":[{"id":"form-and-properties","name":"Form and properties","description":"Connect physical measurements to the tested levodropropizine sample.","findings":[{"id":"qualified-property-values","name":"Qualified property values","description":"Record physical constants with material form, conditions, and experimental or predicted status.","questions":[{"text":"What phase and solid-form identity, if established, describe the sample used for the property measurement?","id":"qualified-property-values-q01","kind":"measurement"},{"text":"What evidence supports its melting range, solubility, and boiling or decomposition behaviour under stated conditions?","id":"qualified-property-values-q02","kind":"provenance"}]}]},{"id":"storage-history","name":"Storage history","description":"Assess whether the material remains within supported stability conditions.","findings":[{"id":"continued-material-suitability","name":"Continued material suitability","description":"Relate observed changes and excursions to batch-specific retest or quarantine decisions.","questions":[{"text":"Which temperature, humidity, light, and container conditions are supported for this grade of levodropropizine?","id":"continued-material-suitability-q01","kind":"provenance"},{"text":"Does an excursion or changed analytical profile trigger retesting or quarantine under the applicable specification?","id":"continued-material-suitability-q02","kind":"action"}]}]}]},{"id":"antitussive-role-and-evidence","name":"Antitussive role and evidence","description":"Link the substance to pharmacological evidence without embedding prescribing decisions.","layers":[{"id":"pharmacological-interpretation","name":"Pharmacological interpretation","description":"Separate supported functional classification from detailed mechanistic hypotheses.","findings":[{"id":"mechanism-evidence-boundary","name":"Mechanism evidence boundary","description":"Retain the evidence type and uncertainty behind claims about peripheral antitussive action.","questions":[{"text":"Which evidence supports a peripheral antitussive effect specifically for levodropropizine?","id":"mechanism-evidence-boundary-q01","kind":"provenance"},{"text":"Which proposed nerve, mediator, or molecular-target effects remain hypotheses rather than established mechanisms?","id":"mechanism-evidence-boundary-q02","kind":"definition"}]}]},{"id":"clinical-transfer-boundary","name":"Clinical transfer boundary","description":"Prevent substance-level evidence from becoming an unsupported product or patient recommendation.","findings":[{"id":"evidence-applicability","name":"Evidence applicability","description":"Associate efficacy and safety findings with the actual substance, formulation, population, and study conditions.","questions":[{"text":"Was the cited result obtained with levodropropizine, racemic dropropizine, or a combination product?","id":"evidence-applicability-q01","kind":"boundary"},{"text":"Which formulation, population, and clinical-context limitations must accompany a handoff to a treatment model?","id":"evidence-applicability-q02","kind":"action"}]}]}]},{"id":"handling-and-regulatory-applicability","name":"Handling and regulatory applicability","description":"Determine which safety records and permissions apply to a specific material and proposed activity.","layers":[{"id":"bulk-material-safety","name":"Bulk material safety","description":"Resolve hazards for the supplied substance and its handling conditions.","findings":[{"id":"applicable-hazard-evidence","name":"Applicable hazard evidence","description":"Use current, substance-matched safety documentation without interpreting missing classifications as evidence of safety.","questions":[{"text":"Which SDS and jurisdictional GHS classification apply to the supplied levodropropizine material?","id":"applicable-hazard-evidence-q01","kind":"provenance"},{"text":"What documented exposure limits or task-specific controls apply to weighing, dust generation, spills, and disposal?","id":"applicable-hazard-evidence-q02","kind":"action"}]}]},{"id":"jurisdiction-and-intended-use","name":"Jurisdiction and intended use","description":"Link proposed activities to the relevant substance records and product permissions.","findings":[{"id":"permission-scope","name":"Permission scope","description":"Keep identity registration, grade compliance, and medicinal product authorisation separate.","questions":[{"text":"Which jurisdiction, date, and intended activity govern whether this levodropropizine material may be supplied or used?","id":"permission-scope-q01","kind":"boundary"},{"text":"What authoritative record supports that permission, and does it apply to the substance or only to a specified medicinal product?","id":"permission-scope-q02","kind":"provenance"}]}]}]},{"id":"evidence-and-external-alignment","name":"Evidence and external alignment","description":"What the world already says about this thing, gathered so the model can be checked against it.","layers":[{"id":"reported-evidence","name":"Reported evidence","description":"Findings from the breadth pass, kept separate from the structural claims.","findings":[{"id":"evidence-confidence-notes","name":"Check these first","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these check these first hold for the sense of levodropropizine this model covers, and on what evidence?","id":"evidence-confidence-notes-q01","kind":"provenance"}]},{"id":"evidence-identifiers","name":"Identifiers and schemes","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these identifiers and schemes hold for the sense of levodropropizine this model covers, and on what evidence?","id":"evidence-identifiers-q01","kind":"provenance"}]},{"id":"evidence-real-world-use","name":"Real-world use","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these real-world use hold for the sense of levodropropizine this model covers, and on what evidence?","id":"evidence-real-world-use-q01","kind":"provenance"}]},{"id":"evidence-measurements","name":"Typical measurements","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these typical measurements hold for the sense of levodropropizine this model covers, and on what evidence?","id":"evidence-measurements-q01","kind":"provenance"}]},{"id":"evidence-failure-modes-and-hazards","name":"Failure modes and hazards","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these failure modes and hazards hold for the sense of levodropropizine this model covers, and on what evidence?","id":"evidence-failure-modes-and-hazards-q01","kind":"provenance"}]},{"id":"evidence-regional-variation","name":"Regional variation","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these regional variation hold for the sense of levodropropizine this model covers, and on what evidence?","id":"evidence-regional-variation-q01","kind":"provenance"}]},{"id":"evidence-neighbours","name":"Neighbouring kinds and how to tell them apart","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these neighbouring kinds and how to tell them apart hold for the sense of levodropropizine this model covers, and on what evidence?","id":"evidence-neighbours-q01","kind":"provenance"}]}]}]}]},"agentConduct":{"may":["Describe levodropropizine and its approved uses from medicines information.","Report the country-specific authorization status, which differs between markets."],"mustNot":["Recommend it or a dose for a specific person.","Present it as suitable for productive cough or for infants when the labelling says otherwise.","Suggest it as a substitute for medical assessment of a long-lasting cough."],"requiresHuman":["Deciding to give it to a child, pregnant woman or person with other conditions."]},"ethics":{"considerations":["A persistent cough can signal serious illness that symptom relief may mask.","Authorization differs between countries, so advice from one place can mislead in another."],"affectedParties":["Patients with cough","Parents of children"]},"owners":{"steward":"The marketing authorization holder; medicines regulators decide where it may be sold.","roles":[],"masterSystems":["Medicines regulators' product registers"]},"relations":[{"target":"Q910111","type":"parent","note":"registry parent class"}],"interaction":{"identity":{"applicability":"required","items":["Vercy registry: vr.tr.levodropropizine","Wikidata: Q408131 (https://www.wikidata.org/wiki/Q408131)"]},"properties":{"applicability":"required","items":["Molecular composition: C13H20N2O2; molar mass 236.31 g/mol","Stereochemical identity: S configuration; confirmed, inconsistent, or unverified","Enantiomeric composition: S and R fractions in %; enantiomeric excess in %, with method and detection limits","Levodropropizine assay: % mass fraction, with as-is, dried, or anhydrous basis","Impurity profile: Individual and total impurities in % or mg/kg; residual solvents in mg/kg; method-specific limits","Material form and grade: Observed phase; identified solid form if established; water or solvent association; declared grade and specification","Condition-dependent physical properties: Melting range in °C; solubility in g/L at stated temperature, solvent, and pH; boiling or decomposition behaviour with pressure","Storage and retest status: Within specified conditions, excursion recorded, retest due, or unknown","Pharmacological role: Peripherally acting antitussive","Applicable safety and regulatory records: Linked SDS, classification record, substance register, and relevant product authorisation; jurisdiction and revision date"]},"recognition":{"applicability":"required","items":["Supplied as syrup, drops or tablets; identified by its label, not appearance."]},"capabilities":{"applicability":"required","items":["Resolve a supplier's declared material to the stereochemically specific registry identity","Request chemical and chiral analyses appropriate to the intended material grade","Compare batch evidence with a cited specification and flag missing acceptance criteria","Assess whether storage excursions require quarantine or retesting","Find applicable handling requirements and route clinical or product decisions to neighbouring models"]},"hazards":{"applicability":"required","items":["Suppressing a productive cough can retain secretions.","Can cause drowsiness and other adverse effects."]},"interfaces":{"applicability":"required","items":["The WHO Collaborating Centre for Drug Statistics Methodology classifies levodropropizine under ATC code R05DB27 within other cough suppressants."]},"context":{"applicability":"required","items":["Levodropropizine is used as an antitussive medicine for symptomatic relief of nonproductive cough.","It is encountered as a pharmaceutical ingredient, in finished medicines and in analytical laboratories assessing identity and quality."]}},"sources":[{"title":"Wikidata item Q408131: levodropropizine","url":"https://www.wikidata.org/wiki/Q408131","note":"identity and sense of the item"},{"title":"Wikipedia: Levodropropizine","url":"https://en.wikipedia.org/wiki/Levodropropizine","note":"general description of the item"}],"openQuestions":["Which current pharmacopoeial or other authoritative specifications define levodropropizine assay, opposite-enantiomer content, related substances, and accepted analytical methods?","Which experimentally supported physical constants, solid forms, and stability conditions apply to the free substance, and does thermal decomposition preclude a meaningful boiling-point value?","What EC identifier, jurisdiction-specific GHS classifications, and occupational exposure limits can be verified for the exact substance?","How firmly are the proposed peripheral mechanisms established, and which claims rely principally on preclinical evidence?","Which current jurisdiction-specific product authorisations and restrictions are relevant to the intended use, and what limits prevent transferring them to another formulation or material grade?"],"resources":{"spec":"/models/things/publications/thing-q408131/spec.json"},"provenance":{"origin":"thing registry research (pass 2)","builtFrom":["models/things/publications/thing-q408131/spec.json"],"providers":["Codex"],"researchStatus":"unreviewed","generatedAt":"2026-09-12T10:57:02Z","builder":"tools/build_cards.py@1.0.0"},"completeness":{"sections":{"classifiers":"filled","whatItIs":"filled","purpose":"filled","distinguishingFeatures":"filled","structure":"filled","agentConduct":"filled","ethics":"filled","owners":"filled","relations":"filled","interaction.identity":"filled","interaction.properties":"filled","interaction.recognition":"filled","interaction.capabilities":"filled","interaction.hazards":"filled","interaction.interfaces":"filled","interaction.context":"filled","sources":"filled"},"notes":{"_gate":"Published through the thing publication gate 1.0 on 2026-10-07T10:10:30+00:00: completeness 1.00; sense: Wikidata description; 2 live sources; review by codex: pass"},"score":1.0}}